Develops radiopharmaceuticals for cancer diagnosis and treatment.
Jun 2025Revenue $3.63M/yrExpenses $41.8M/yr
No trendCash runway ≈ 10 months from Jun 2025
Figures by year
When will Radiopharm Theranostics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2025, revenue was $3.63M and expenses $41.8M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Jun 2025 | $3.63M | $41.8M | −$38.2M |
| Jun 2024 | $299K | $47.5M | −$47.2M |
| Jun 2023 | $292K | $34.8M | −$34.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.